Chemed Corporation
HealthcareNYSE:CHE · New York Stock Exchange
-$1.56 today
Vol 0.12M · Avg 0.25M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
27.1%
avg 28.5%
ROIC
18.0%
avg 20.1%
ROA
16.2%
avg 16.8%
Analysis
ROE is currently the strongest return metric at 27.1% versus its period average of 28.5%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Kevin J. McNamara | Chief Executive Officer, President & Director | $4.90M | — | 72 | $90,219.00 | 0.68% |
Spencer S. Lee | Executive Vice President | $1.53M | — | 70 | $15,066.00 | 0.11% |
Michael D. Witzeman | Executive Vice President, Controller, Principal Accounting Officer & Chief Financial Officer | $1.30M | — | 55 | $6,073.00 | 0.05% |
Joel L. Wherley | Executive VP and President & CEO of VITAS Healthcare | $1.14M | — | 61 | $1,070.00 | <0.01% |
Brian C. Judkins | Vice President, Secretary & Chief Legal Officer | $875,374.00 | — | 45 | $2,538.00 | 0.02% |
Nathan J. McNamara | Vice President & Chief Strategy Officer | — | — | 38 | $90,219.00 | 0.68% |
Thomas C. Hutton | Vice President & Director | — | — | 75 | $32,553.00 | 0.25% |
Holley R. Schmidt | Vice President & Assistant Controller | — | — | 54 | — | — |
Lisa A. Reinhard | VP, Chief Administrative Officer & Assistant Secretary | — | — | 53 | — | — |
Sherri Warner | Director of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$83,420.00
Sells
11
$10.46M
Net Sentiment
$10.38M
Net selling
Most Active
MCNAMARA KEVIN J
6 transactions
1–10 of 12
Analysis
Insiders reported 1 buys worth $83,420.00 and 11 sells worth $10.46M over the last 12 months. That adds up to net selling of $10.38M. MCNAMARA KEVIN J was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +11.1% | +12.4% (13yr)1 analysts |
| Revenue | N/A | N/A | +2.6% | +5.3% (13yr)1 analysts |
| Net Income | N/A | N/A | +7.3% | +10.7% (13yr)1 analysts |
| EBIT | N/A | N/A | +5.6% | +7.5% (13yr)1 analysts |
Analysis
Recent growth has been strongest in EPS at +11.1% over three years. Forward estimates point to EPS at +12.4% (13yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.40B
BrightSpring Health Services, Inc. Common Stock
NASDAQ:BTSG
$12.26B
Henry Schein, Inc.
NASDAQ:HSIC
$9.26B
Nuvalent, Inc.
NASDAQ:NUVL
$9.07B
Bruker Corporation
NASDAQ:BRKR
$8.26B
AptarGroup, Inc.
NYSE:ATR
$7.51B
Metsera, Inc.
MTSR
$7.43B
Teleflex Incorporated
NYSE:TFX
$5.78B
Stevanato Group S.p.A.
NYSE:STVN
$4.66B
Option Care Health, Inc.
NASDAQ:OPCH
$3.26B
Who manages CHE?
Chemed Corporation (CHE) lists 10 active executives. The top listed executive is Brian C. Judkins, Vice President, Secretary & Chief Legal Officer.
Are CHE insiders buying or selling?
Recent insider activity shows net buying of $23.52M.
Explore More
Continue the stock analysis
Jump to another research area for this company.